Literature DB >> 34561272

TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.

Chiara Berlato1, Eleni Maniati1, Robin Delaine-Smith1, Laura S M Lecker1, Oliver M T Pearce1, Owen Heath1, Samuel J Nichols1, Caterina Trevisan2,3, Marian Novak4, Jacqueline McDermott1, James D Brenton5, Pedro R Cutillas1, Vinothini Rajeeve1, Ana Hennino6, Ronny Drapkin7, Daniela Loessner1, Frances R Balkwill8.   

Abstract

The tumor microenvironment evolves during malignant progression, with major changes in nonmalignant cells, cytokine networks, and the extracellular matrix (ECM). In this study, we aimed to understand how the ECM changes during neoplastic transformation of serous tubal intraepithelial carcinoma lesions (STIC) into high-grade serous ovarian cancers (HGSOC). Analysis of the mechanical properties of human fallopian tubes (FT) and ovaries revealed that normal FT and fimbria had a lower tissue modulus, a measure of stiffness, than normal or diseased ovaries. Proteomic analysis of the matrisome fraction between FT, fimbria, and ovaries showed significant differences in the ECM protein TGF beta induced (TGFBI, also known as βig-h3). STIC lesions in the fimbria expressed high levels of TGFBI, which was predominantly produced by CD163-positive macrophages proximal to STIC epithelial cells. In vitro stimulation of macrophages with TGFβ and IL4 induced secretion of TGFBI, whereas IFNγ/LPS downregulated macrophage TGFBI expression. Immortalized FT secretory epithelial cells carrying clinically relevant TP53 mutations stimulated macrophages to secrete TGFBI and upregulated integrin αvβ3, a putative TGFBI receptor. Transcriptomic HGSOC datasets showed a significant correlation between TGFBI expression and alternatively activated macrophage signatures. Fibroblasts in HGSOC metastases expressed TGFBI and stimulated macrophage TGFBI production in vitro. Treatment of orthotopic mouse HGSOC tumors with an anti-TGFBI antibody reduced peritoneal tumor size, increased tumor monocytes, and activated β3-expressing unconventional T cells. In conclusion, TGFBI may favor an immunosuppressive microenvironment in STICs that persists in advanced HGSOC. Furthermore, TGFBI may be an effector of the tumor-promoting actions of TGFβ and a potential therapeutic target. SIGNIFICANCE: Analysis of ECM changes during neoplastic transformation reveals a role for TGFBI secreted by macrophages in immunosuppression in early ovarian cancer. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34561272     DOI: 10.1158/0008-5472.CAN-21-0536

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer.

Authors:  Zhijie Xu; Bi Peng; Fanhua Kang; Wenqin Zhang; Muzhang Xiao; Jianbo Li; Qianhui Hong; Yuan Cai; Wei Liu; Yuanliang Yan; Jinwu Peng
Journal:  Front Cell Dev Biol       Date:  2022-06-09

2.  Conditioned media of pancreatic cancer cells and pancreatic stellate cells induce myeloid-derived suppressor cells differentiation and lymphocytes suppression.

Authors:  Yuen Ping Chong; Evelyn Priya Peter; Feon Jia Ming Lee; Chu Mun Chan; Shereen Chai; Lorni Poh Chou Ling; Eng Lai Tan; Sook Han Ng; Atsushi Masamune; Siti Aisyah Abd Ghafar; Norsharina Ismail; Ket Li Ho
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

3.  Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer.

Authors:  Xiaoge Ni; Can Chen; Guoliang Cui; Wei Ding; Jinhui Liu
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

4.  Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

Authors:  Frank G Lawton; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-03-24

Review 5.  The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.

Authors:  Sabrina J Ritch; Carlos M Telleria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

6.  TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling.

Authors:  Peng Peng; Hongtao Zhu; Dan Liu; Zirong Chen; Xiaolin Zhang; Zhongyin Guo; Minhai Dong; Lijun Wan; Po Zhang; Guohao Liu; Suojun Zhang; Fangyong Dong; Feng Hu; Fangling Cheng; Shijun Huang; Dongsheng Guo; Bin Zhang; Xingjiang Yu; Feng Wan
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

Review 7.  Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics.

Authors:  Emanuela Guerra; Roberta Di Pietro; Mariangela Basile; Marco Trerotola; Saverio Alberti
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

Review 8.  Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook.

Authors:  Yongsheng Ruan; Libai Chen; Danfeng Xie; Tingting Luo; Yiqi Xu; Tao Ye; Xiaona Chen; Xiaoqin Feng; Xuedong Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-07       Impact factor: 6.055

9.  A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3.

Authors:  Christelle de la Fouchardière; Pia Gamradt; Sylvie Chabaud; Maxime Raddaz; Ellen Blanc; Olivier Msika; Isabelle Treilleux; Sophie Bachy; Anne Cattey-Javouhey; Pierre Guibert; Matthieu Sarabi; Pauline Rochefort; Pamela Funk-Debleds; Clélia Coutzac; Isabelle Ray-Coquard; Patrice Peyrat; Pierre Meeus; Michel Rivoire; Aurélien Dupré; Ana Hennino
Journal:  J Pers Med       Date:  2022-04-12

10.  The Role of the Extracellular Matrix and Tumor-Infiltrating Immune Cells in the Prognostication of High-Grade Serous Ovarian Cancer.

Authors:  Yuri Belotti; Elaine Hsuen Lim; Chwee Teck Lim
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.